Ionis Pharmaceuticals (IONS) Operating Expenses (2009 - 2026)

Ionis Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $363.5 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 30.54% year-over-year to $363.5 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 18.56% YoY), while the FY2025 annual figure was $1.3 billion, up 12.3% from the prior year.
• Operating Expenses was $363.5 million for Q1 2026 at Ionis Pharmaceuticals, down from $417.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $417.8 million in Q4 2025 to a low of $199.4 million in Q1 2022.
• Historically, Operating Expenses has averaged $294.6 million across 5 years, with a median of $287.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses jumped 64.04% in 2022, then retreated 8.14% in 2023.
• A 5-year view of Operating Expenses shows it stood at $359.9 million in 2022, then fell by 8.14% to $330.6 million in 2023, then advanced by 2.05% to $337.4 million in 2024, then advanced by 23.83% to $417.8 million in 2025, then declined by 12.99% to $363.5 million in 2026.
• The last three Operating Expenses figures came in at $363.5 million (Q1 2026), $417.8 million (Q4 2025), and $316.9 million (Q3 2025), per Business Quant data.